• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三氧化二砷通过协同抑制 LIF/JAK1/STAT3 和 NF-κB 信号通路诱导肝癌肿瘤干细胞分化。

Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.

机构信息

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China.

出版信息

Clin Transl Med. 2021 Feb;11(2):e335. doi: 10.1002/ctm2.335.

DOI:10.1002/ctm2.335
PMID:33634982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7901720/
Abstract

OBJECTIVE

Differentiation-inducing therapy for tumors is a strategy that aims to induce the differentiation and maturation of cancer stem cells (CSCs). The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown.

METHODS

In the present study, we explored the ATO-induced differentiation of CSCs in HCC by detecting the expression of CSC-related markers and tumorigenicity variation in vivo and in vitro. We developed a combined chemotherapeutic approach to HCC by characterizing the effects of combinatorial treatment with 5-fluorouracil (5-FU)/cisplatin and ATO in vitro and in patient-derived xenograft models. Changes in gene expression patterns were investigated by gene microarray analysis.

RESULTS

ATO effectively induced differentiation of CSCs by downregulation of CSC-related genes and suppression of tumorigenicity capability. Combinatorial treatment with ATO and 5-FU/cisplatin significantly enhanced therapeutic effects in HCC cells compared with the treatment with 5-FU/cisplatin alone. Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect.

CONCLUSIONS

ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways. These results offer new insights for the clinical treatment of HCC.

摘要

目的

肿瘤诱导分化治疗是一种旨在诱导癌症干细胞（CSC）分化和成熟的策略。三氧化二砷（ATO）在肝细胞癌（HCC）中的诱导分化能力及其潜在机制尚不清楚。

方法

在本研究中，我们通过检测CSC 相关标志物的表达和体内外肿瘤发生能力的变化，探讨了 ATO 诱导 HCC 中 CSCs 分化的情况。我们通过体外和患者来源的异种移植模型研究了 5-氟尿嘧啶（5-FU）/顺铂与 ATO 联合治疗的效果，开发了一种联合化疗治疗 HCC 的方法。通过基因微阵列分析研究了基因表达模式的变化。

结果

ATO 通过下调 CSC 相关基因和抑制肿瘤发生能力，有效地诱导 CSCs 分化。与单独使用 5-FU/顺铂相比，ATO 与 5-FU/顺铂联合治疗显著增强了 HCC 细胞的治疗效果。ATO 和 5-FU/顺铂协同抑制 LIF/JAK1/STAT3 和 NF-kB 信号通路是其分化作用的潜在分子机制。

结论

ATO 通过协同抑制 LIF/JAK1/STAT3 和 NF-kB 信号通路，诱导 HCC CSCs 分化，并增强 5-FU/顺铂的细胞毒性作用。这些结果为 HCC 的临床治疗提供了新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/9ff979a105b0/CTM2-11-e335-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/c4be2e38a40d/CTM2-11-e335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/1d6aecfc918b/CTM2-11-e335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/1e3b5d19a6d2/CTM2-11-e335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/a707309e39f8/CTM2-11-e335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/9ff979a105b0/CTM2-11-e335-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/c4be2e38a40d/CTM2-11-e335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/1d6aecfc918b/CTM2-11-e335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/1e3b5d19a6d2/CTM2-11-e335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/a707309e39f8/CTM2-11-e335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d0e/7901720/9ff979a105b0/CTM2-11-e335-g005.jpg

相似文献

1
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.三氧化二砷通过协同抑制 LIF/JAK1/STAT3 和 NF-κB 信号通路诱导肝癌肿瘤干细胞分化。
Clin Transl Med. 2021 Feb;11(2):e335. doi: 10.1002/ctm2.335.
2
ZnAs@SiO nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling.ZnAs@SiO 纳米颗粒作为一种潜在的抗肿瘤药物，通过 SHP-1/JAK2/STAT3 信号通路靶向肝癌中的干性和上皮-间充质转化。
Theranostics. 2019 Jun 9;9(15):4391-4408. doi: 10.7150/thno.32462. eCollection 2019.
3
Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.三氧化二砷通过靶向 SRF/MCM7 复合物抑制肝癌干细胞和转移。
Cell Death Dis. 2019 Jun 11;10(6):453. doi: 10.1038/s41419-019-1676-0.
4
Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.三氧化二砷通过靶向调控 GLI1 表达诱导 CD133+肝癌细胞分化并延长小鼠术后生存期。
J Hematol Oncol. 2014 Mar 30;7:28. doi: 10.1186/1756-8722-7-28.
5
Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3η/NF-κB feedback loop.三氧化二砷逆转肝癌的化疗耐药性：14-3-3η/NF-κB 反馈环的靶向干预。
J Exp Clin Cancer Res. 2018 Dec 20;37(1):321. doi: 10.1186/s13046-018-1005-y.
6
Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.高三尖杉酯碱与三氧化二砷协同杀伤急性髓系白血病干细胞及其作用机制。
J Exp Clin Cancer Res. 2019 Jul 15;38(1):308. doi: 10.1186/s13046-019-1295-8.
7
De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties.三氧化二砷去甲基化 miR-148a 通过抑制 NF-κB 通路和 CSC 样特性增强对化疗的敏感性。
Exp Cell Res. 2020 Jan 15;386(2):111739. doi: 10.1016/j.yexcr.2019.111739. Epub 2019 Nov 20.
8
Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.抑瘤素 M 通过诱导肝细胞分化使上皮细胞黏附分子阳性肝癌干细胞对 5-氟尿嘧啶敏感。
Cancer Res. 2010 Jun 1;70(11):4687-97. doi: 10.1158/0008-5472.CAN-09-4210. Epub 2010 May 18.
9
Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.淫羊藿苷与三氧化二砷协同抑制人肝细胞癌。
Cell Biochem Biophys. 2014 Mar;68(2):427-36. doi: 10.1007/s12013-013-9724-3.
10
C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway.C 末端截短的乙型肝炎病毒 X 蛋白通过 STAT3/Nanog 信号通路调节肿瘤发生、自我更新和耐药性。
Oncotarget. 2017 Apr 4;8(14):23507-23516. doi: 10.18632/oncotarget.15183.

引用本文的文献

1
Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors.肝细胞癌干细胞：基于小分子抑制剂的研究现状
Cell Death Dis. 2025 Sep 1;16(1):666. doi: 10.1038/s41419-025-07983-5.
2
A bibliometric and visual analysis of Jak1 to explore trends and frontiers.对Jak1进行文献计量与可视化分析以探究趋势和前沿。
Front Oncol. 2025 Jul 17;15:1537508. doi: 10.3389/fonc.2025.1537508. eCollection 2025.
3
Synergic chemotherapeutic effects of docetaxel and carboplatin show cytotoxic and apoptotic effects in liver cancer nursing care: Role of oxidative stress and hemocompatibility.

本文引用的文献

1
Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target.球体形成培养富集肝癌干细胞并揭示硬脂酰辅酶 A 去饱和酶 1 作为潜在的治疗靶点。
BMC Cancer. 2019 Aug 1;19(1):760. doi: 10.1186/s12885-019-5963-z.
2
Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.三氧化二砷通过靶向 SRF/MCM7 复合物抑制肝癌干细胞和转移。
Cell Death Dis. 2019 Jun 11;10(6):453. doi: 10.1038/s41419-019-1676-0.
3
The expanding roles of long non-coding RNAs in the regulation of cancer stem cells.
多西他赛与卡铂的协同化疗作用在肝癌护理中显示出细胞毒性和凋亡作用：氧化应激与血液相容性的作用
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 28. doi: 10.1007/s00210-025-04295-5.
4
Targeting LIF With Cyclovirobuxine D to Suppress Tumor Progression via LIF/p38MAPK/p62-Modulated Mitophagy in Hepatocellular Carcinoma.环维黄杨星D靶向白血病抑制因子通过LIF/p38丝裂原活化蛋白激酶/p62调节的线粒体自噬抑制肝癌进展
MedComm (2020). 2025 May 24;6(6):e70227. doi: 10.1002/mco2.70227. eCollection 2025 Jun.
5
Patient-derived xenograft model: Applications and challenges in liver cancer.患者来源的异种移植模型：在肝癌中的应用与挑战
Chin Med J (Engl). 2025 Jun 5;138(11):1313-1323. doi: 10.1097/CM9.0000000000003480. Epub 2025 May 19.
6
Study on the Mechanism of QRICH1 Mediating PRMT1 to Regulate the Arginine Methylation Modification of cGAS to Promote Arsenics-Induced Pyroptosis in Hepatocellular Carcinoma Cells.QRICH1介导PRMT1调控cGAS精氨酸甲基化修饰促进肝癌细胞砷诱导的焦亡机制研究
J Hepatocell Carcinoma. 2025 Mar 19;12:597-614. doi: 10.2147/JHC.S505266. eCollection 2025.
7
S100A8 promotes tumor progression by inducing phenotypic polarization of microglia through the TLR4/IL-10 signaling pathway in glioma.S100A8通过胶质瘤中TLR4/IL-10信号通路诱导小胶质细胞表型极化来促进肿瘤进展。
J Natl Cancer Cent. 2024 Jul 23;4(4):369-381. doi: 10.1016/j.jncc.2024.07.001. eCollection 2024 Dec.
8
Extinguishing the flames of inflammation: retardant effect of chlorquinaldol on NLRP3-driven diseases.扑灭炎症之火：氯喹那多对NLRP3驱动疾病的抑制作用
Mol Med. 2024 Dec 19;30(1):245. doi: 10.1186/s10020-024-01016-1.
9
Insight into the mechanisms regulating liver cancer stem cells by hepatitis B virus X protein.深入了解乙型肝炎病毒X蛋白调控肝癌干细胞的机制。
Infect Agent Cancer. 2024 Nov 11;19(1):56. doi: 10.1186/s13027-024-00618-y.
10
Targeting catalase in cancer.靶向肿瘤细胞中的过氧化氢酶。
Redox Biol. 2024 Nov;77:103404. doi: 10.1016/j.redox.2024.103404. Epub 2024 Oct 19.
长非编码 RNA 在癌症干细胞调控中的作用不断扩大。
Int J Biochem Cell Biol. 2019 Mar;108:17-20. doi: 10.1016/j.biocel.2019.01.003. Epub 2019 Jan 7.
4
High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen.采用基于全反式维甲酸和三氧化二砷的方案成功治疗具有异常T/髓系免疫表型的高危急性早幼粒细胞白血病。
J Hematop. 2018 Sep;11(3):67-74. doi: 10.1007/s12308-018-0329-z. Epub 2018 Aug 9.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Molecular remission as a therapeutic objective in acute promyelocytic leukemia.分子缓解作为急性早幼粒细胞白血病的治疗目标。
Leukemia. 2018 Aug;32(8):1671-1678. doi: 10.1038/s41375-018-0219-5. Epub 2018 Jul 19.
7
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
8
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
9
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.2015 年全球疾病负担研究：1990 年至 2015 年全球、区域和国家一级原发性肝癌及相关病因负担。
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. doi: 10.1001/jamaoncol.2017.3055.
10
Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells.一种具有消除干细胞样癌细胞能力的新型活性氧调节剂在体外和体内对癌症生长的抑制作用
Cell Death Dis. 2017 Jun 22;8(6):e2887. doi: 10.1038/cddis.2017.272.